JP7458032B2 - 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 - Google Patents

出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Download PDF

Info

Publication number
JP7458032B2
JP7458032B2 JP2020561786A JP2020561786A JP7458032B2 JP 7458032 B2 JP7458032 B2 JP 7458032B2 JP 2020561786 A JP2020561786 A JP 2020561786A JP 2020561786 A JP2020561786 A JP 2020561786A JP 7458032 B2 JP7458032 B2 JP 7458032B2
Authority
JP
Japan
Prior art keywords
centaquine
blood
pharmaceutical composition
renal
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523125A5 (cg-RX-API-DMAC7.html
JP2021523125A (ja
Inventor
アニル グラティ,
マニシュ ラヴハル,
バウナ カティア,
アビシェーク クマール シン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmazz Inc
Original Assignee
Pharmazz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmazz Inc filed Critical Pharmazz Inc
Publication of JP2021523125A publication Critical patent/JP2021523125A/ja
Publication of JP2021523125A5 publication Critical patent/JP2021523125A5/ja
Application granted granted Critical
Publication of JP7458032B2 publication Critical patent/JP7458032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020561786A 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Active JP7458032B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666675P 2018-05-03 2018-05-03
US62/666,675 2018-05-03
IN201841019588 2018-05-25
IN201841019588 2018-05-25
PCT/US2019/030652 WO2019213558A1 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Publications (3)

Publication Number Publication Date
JP2021523125A JP2021523125A (ja) 2021-09-02
JP2021523125A5 JP2021523125A5 (cg-RX-API-DMAC7.html) 2022-05-13
JP7458032B2 true JP7458032B2 (ja) 2024-03-29

Family

ID=68386694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561786A Active JP7458032B2 (ja) 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Country Status (9)

Country Link
US (1) US12629406B2 (cg-RX-API-DMAC7.html)
EP (2) EP3813942B1 (cg-RX-API-DMAC7.html)
JP (1) JP7458032B2 (cg-RX-API-DMAC7.html)
CN (1) CN112469474A (cg-RX-API-DMAC7.html)
AU (1) AU2019262612B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022395A2 (cg-RX-API-DMAC7.html)
ES (1) ES2978951T3 (cg-RX-API-DMAC7.html)
PL (1) PL3813942T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019213558A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
WO2022240964A1 (en) * 2021-05-11 2022-11-17 Pharmazz, Inc. Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19)
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
IN202411028038A (cg-RX-API-DMAC7.html) * 2024-04-04 2025-05-23

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
JP2010523584A (ja) 2007-04-02 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピリミジン
JP2010523694A (ja) 2007-04-10 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 高血圧治療のための置換重水素濃縮チオフェン
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
JP2012525422A (ja) 2009-04-30 2012-10-22 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
JP2015530385A (ja) 2012-08-31 2015-10-15 ファーマズ,インコーポレイテッド 低血圧蘇生のための方法および組成物
JP2016523969A (ja) 2013-07-08 2016-08-12 ミッドウェスタン ユニバーシティ エンドセリンb受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ 1―m―トリル―4―(B―2―キノリエチル)―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
EP0126327A1 (en) 1983-04-26 1984-11-28 Frank J. Macri Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20050009847A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
JP4976412B2 (ja) * 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
JP2009530407A (ja) 2006-03-23 2009-08-27 アミリン・ファーマシューティカルズ,インコーポレイテッド 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
PL2182977T3 (pl) 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
JP2025149692A (ja) 2024-03-26 2025-10-08 ローム株式会社 無線通信回路
JP2026006612A (ja) 2024-06-28 2026-01-16 多摩川精機株式会社 温度検出体固定用溝付き絶縁キャップ、回転電機の温度検出体固定構造、温度検出体固定済み回転電機、回転電機の温度検出体固定方法、および回転電機製造装置

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
JP2010523584A (ja) 2007-04-02 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピリミジン
JP2010523694A (ja) 2007-04-10 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 高血圧治療のための置換重水素濃縮チオフェン
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
JP2012525422A (ja) 2009-04-30 2012-10-22 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
JP2015530385A (ja) 2012-08-31 2015-10-15 ファーマズ,インコーポレイテッド 低血圧蘇生のための方法および組成物
JP2016523969A (ja) 2013-07-08 2016-08-12 ミッドウェスタン ユニバーシティ エンドセリンb受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIGUEL, C. D. et al.,Endothelinreceptor-specific control of endoplasmic reticulum stress and apoptosis in thekidney,Sci. Rep.,2017年,vol. 7, 43152,p. 1-13
SRIMAL, R. C. et al.,Studies on 2-2-(4-(3-methylphenyl)1-piperazinyl)ethyl quinoline (centhaquin), a centrallyacting antihypertensive. II, Effect on cardiohaemodynamics,Asia pacific journal ofpharmacology,1990年,Vol 5, No. 3,pp 185-190
菱田 明,急性腎不全,日腎会誌,2002年,vol. 44, no. 2,p. 94-101

Also Published As

Publication number Publication date
CA3099128A1 (en) 2019-11-07
US20210169978A1 (en) 2021-06-10
EP3813942A4 (en) 2022-01-19
EP3813942B1 (en) 2024-04-17
CN112469474A (zh) 2021-03-09
BR112020022395A2 (pt) 2021-04-13
AU2019262612A1 (en) 2020-11-26
EP4364811A3 (en) 2024-07-10
EP4364811A2 (en) 2024-05-08
ES2978951T3 (es) 2024-09-23
PL3813942T3 (pl) 2024-07-22
WO2019213558A1 (en) 2019-11-07
EP3813942A1 (en) 2021-05-05
US12629406B2 (en) 2026-05-19
JP2021523125A (ja) 2021-09-02
AU2019262612B2 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
AU2019262612B2 (en) Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
AU2012388759B2 (en) Methods and compositions for hypotensive resuscitation
KR100445946B1 (ko) 폐고혈압 치료법
US20200375953A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
PT1401416E (pt) Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
CA3099128C (en) Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
WO2021037212A9 (zh) 用于对抗代谢疾病的组合物及其用途
Abdallah New trends in pharmacological treatment of acute kidney injury
CN107243004B (zh) 一种五味子乙素在药物制备中的应用
JP6861162B2 (ja) アポエクオリン含有組成物および神経細胞の炎症を治療するためのアポエクオリンの使用方法
AU2017249459A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
CN117396505A (zh) 治疗炎症的方法
Briyal et al. Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
JP2019513727A (ja) レンバチニブ及びエベロリムスを用いた腎細胞癌の治療
AU2015203036A1 (en) Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
Saleem et al. Nephroprotective effect of octreotide and liraglutide in renal ischemia reperfusion injury in mice
KR20180128452A (ko) Nsaid-유도된 심혈관, 뇌혈관, 또는 신혈관 부작용을 치료하는 방법
KR20200139447A (ko) 항염증 조성물
Hsieh Pancreatic expression of trpa1, its role in insulin secretion and its possible effect on postprandial blood glucose levels
Buckley et al. Dr Maria Buckley, Department Pharmacology & Therapeutics, Department of Physiology, APC Microbiome Institute, University College Cork, Cork, Ireland.“Ghrelin enhances GLP-1 induced neuronal activation in the distal colon.”
KR20020045552A (ko) 만성 폐색성 폐질환의 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240308

R150 Certificate of patent or registration of utility model

Ref document number: 7458032

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150